1. Telix Surges as FDA Accepts Review of Brain Cancer Imaging Agent TLX101-CDx
Telix Pharmaceuticals saw its stock rise after the U.S. Food and Drug Administration (FDA) formally accepted its Biologics License Application (BLA) for TLX101-CDx, a novel imaging agent designed to detect brain cancer. This regulatory milestone triggers a standard 10-month review period, putting the company on a clear...